Cantor Fitzgerald initiated coverage on shares of Disc Medicine Opco (NASDAQ:IRON – Get Rating) in a report released on Friday morning, The Fly reports. The firm issued an overweight rating and a $45.00 price target on the stock. Several other research analysts have also recently weighed in on IRON. Lifesci Capital reissued an outperform rating […]
Disc Medicine Opco Inc (NASDAQ:IRON – Get Rating) – Equities research analysts at Lifesci Capital issued their Q1 2023 EPS estimates for Disc Medicine Opco in a report issued on Monday, April 24th. Lifesci Capital analyst R. Katkhuda forecasts that the company will post earnings of ($0.79) per share for the quarter. Lifesci Capital has […]
Stifel Nicolaus initiated coverage on shares of Disc Medicine Opco (NASDAQ:IRON – Get Rating) in a report issued on Thursday, The Fly reports. The firm issued a buy rating and a $37.00 price objective on the stock. IRON has been the topic of a number of other research reports. BMO Capital Markets assumed coverage on […]
Disc Medicine Opco (NASDAQ:IRON – Get Rating) and ProPhase Labs (NASDAQ:PRPH – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership. Institutional and Insider Ownership 75.4% of Disc Medicine […]
Shares of Disc Medicine Opco Inc (NASDAQ:IRON – Get Rating) have earned a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued ratings on […]